EP0888138A1 - Formulations topiques pour traiter le psoriasis de l'ongle - Google Patents

Formulations topiques pour traiter le psoriasis de l'ongle

Info

Publication number
EP0888138A1
EP0888138A1 EP97905085A EP97905085A EP0888138A1 EP 0888138 A1 EP0888138 A1 EP 0888138A1 EP 97905085 A EP97905085 A EP 97905085A EP 97905085 A EP97905085 A EP 97905085A EP 0888138 A1 EP0888138 A1 EP 0888138A1
Authority
EP
European Patent Office
Prior art keywords
formulation
formulation according
spreading
film former
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97905085A
Other languages
German (de)
English (en)
Inventor
Walter Petri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of EP0888138A1 publication Critical patent/EP0888138A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action

Definitions

  • Dithranol (local), PUVA, glucocorticoids and vitamin D analogues (local) or systemic methotrexate, retinoids, cyclosporin A treated.
  • EP 0 634 170 describes formulations for the treatment of psoriasis.
  • the invention aims to provide a formulation which does not have the disadvantages described above or has them only to a minor extent.
  • the object is achieved by using a formulation which consists of the active ingredient, at least one spreading solvent, a volatile solvent and a water-insoluble film former for the manufacture of a medicament for the treatment of nail psoriasis.
  • Spreading solvents are understood to mean compounds which are found in a test system, as in Pharm. Research / Drug Res. 31 (II), 8a, p. 1 334, 1981, give the formulations according to the invention a higher spread number than Example 12 from EP 0 226 984.
  • Volatile solvents are understood to mean compounds which have a boiling point which is below 80 ° C.
  • active ingredients come e.g. in question: leflunomide and its metabolite A 77 1726, propentofylline, pentoxifylline, cyclosporin A or glucocorticoids, e.g. Alclometasone dipropionate, amcinonide, beclomethasone dipropionate, Bendacort, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, budesonide, chlorquinaldol, clioquinol, clobetasol propionate, clobetasone butyrate, desonide, desoximetasone, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone, difluprednate, fluazacort, flucinolone acetonide, fluclorolone, fludroxycortide, Flumathasonpivalat, Fluocinolonacetonide, Fluocino
  • Penetration-promoting substances are also used in these formulations, e.g. Oleyl oleate, n-octanol, N-methylpyrrolidone, hexyl laurate.
  • Suitable film formers are, for example, substances based on cellulose nitrate or physiologically harmless polymers, as are customary, for example, in cosmetics, preferably as a mixture with cellulose nitrate.
  • Examples include polyvinyl acetate and partially saponified polyvinyl acetate, copolymers of vinyl acetate on the one hand and acrylic acid or crotonic acid or Monoalkyl maleates on the other hand, tertiary copolymers of vinyl acetate on the one hand and crotonic acid and vinyl neodecanoate, or crotonic acid and vinyl propionate on the other hand, copolymers of methyl vinyl ether and monoalkyl maleate, in particular as monobutyl maleate, copolymers of Fettklavinylester and acrylic acid or methacrylic acid, copolymers of N-vinylpyrrolidone, methacrylic acid and alkyl methacrylate, copolymers of acrylic acid and methacrylic acid
  • Suitable physiologically acceptable solvents are substances such as hydrocarbons, alcohols, ethers, ketones and esters customary in cosmetics, in particular ethanol, isopropanol or acetic acid esters of monohydric alcohols, such as ethyl and butyl acetate.
  • the formulations according to the invention can furthermore contain additives customary in cosmetics, such as phthalate or camphor-based plasticizers, dyes or colored pigments, pearlescent agents, sedimentation retardants, sulfonamide resins, silicates, fragrances, surface-active substances, for example wetting agents such as sodium dioctylsulfosuccinate (DONS) and / or PEG-400 monolaurate, Tween ® 80, lanolin derivatives, photoprotective agents such as 2-hydroxy-4-methoxybenzophenone, antibacterial and antimycotic active substances, substances with a keratolytic and / or keratoplastic action, such as ammonium sulfite, esters and salts of thioglycolic acid, urea, allantoin, enzymes, Salicylic acid, complexing agents such as edetic acid and its salts and pH-adjusting substances.
  • Colored or pigmented formulations have the advantage, for example, that they can be
  • the total concentration of the antipsoriatic active ingredients is from 0.1 to 10 percent by weight (hereinafter abbreviated as%), in particular from 0.5% to 5%.
  • the concentration of the spreading solvent is from 0.1% to 10%.
  • the concentration of the film former is from 3.0% to 35%.
  • the total concentration of volatile solvents is from 50% to 90%.
  • compositions according to the invention have the following compositions:
  • silica gel layer determined according to the method given in Pharmaceutical Research / Drug Res. 31 (II), 8a, p. 1334, 1981, which was modified for measuring liquid formulations as follows.
  • the liquid formulation to be examined was applied into the inner lumen of a glass ring which was placed in the center of the thin-layer plate. In each case 100 ⁇ l were applied at 21 ° C.
  • the total area of the spreading capacity - idealized as a circular area - was determined by determining the final value of Z.
  • Relative spreading capacity spreading capacity of the formulation divided by spreading capacity of the comparison formulation.
  • IPP isopropyl palmitate
  • An anhydrous, volatile solvent or solvent mixture is introduced and, with stirring, a spreading solvent, a film former and an antipsoriatic active ingredient are added in succession so that a solution or a suspension is formed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des formulations appropriées pour traiter le psoriasis de l'ongle et contenant un principe actif antipsoriasique, au moins un solvant d'étalement, au moins un solvant volatil et un agent filmogène.
EP97905085A 1996-03-16 1997-02-26 Formulations topiques pour traiter le psoriasis de l'ongle Withdrawn EP0888138A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19610482 1996-03-16
DE19610482 1996-03-16
PCT/EP1997/000905 WO1997034644A1 (fr) 1996-03-16 1997-02-26 Formulations topiques pour traiter le psoriasis de l'ongle

Publications (1)

Publication Number Publication Date
EP0888138A1 true EP0888138A1 (fr) 1999-01-07

Family

ID=7788561

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97905085A Withdrawn EP0888138A1 (fr) 1996-03-16 1997-02-26 Formulations topiques pour traiter le psoriasis de l'ongle

Country Status (8)

Country Link
EP (1) EP0888138A1 (fr)
JP (1) JP2000512265A (fr)
KR (1) KR20000064607A (fr)
AU (1) AU1876797A (fr)
BR (1) BR9708081A (fr)
CA (1) CA2248977A1 (fr)
WO (1) WO1997034644A1 (fr)
ZA (1) ZA972180B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO118174B1 (ro) * 1997-08-21 2003-03-28 Aventis Pharma Deutschland Gmbh Lac de unghii şi utilizarea acestuia
TR200600888T1 (tr) * 2003-08-25 2006-08-21 Bioequal Ag Farmasötik ve kozmetik formülasyonlar.
CA2610755A1 (fr) * 2005-06-10 2006-12-14 Galderma S.A. Methode de liberation controlee d'un medicament a travers la peau
CA2775393C (fr) * 2012-05-02 2014-04-29 Samy Saad Formulations pharmaceutiques topiques non aqueuses
KR102327827B1 (ko) 2019-11-01 2021-11-18 한국과학기술연구원 강황 추출물을 유효성분으로 포함하고 자외선 처리를 포함하는 건선 개선용 조성물
KR102461001B1 (ko) 2020-09-14 2022-11-01 한국과학기술연구원 술패랭이꽃 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102451304B1 (ko) 2020-09-14 2022-10-07 한국과학기술연구원 꿩의다리속 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102527907B1 (ko) 2020-09-14 2023-05-03 한국과학기술연구원 무산상자 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR20230041257A (ko) 2021-09-17 2023-03-24 한국과학기술연구원 시미시푸고라이드 에이를 유효성분으로 포함하는 건선 개선용 조성물
KR20230041255A (ko) 2021-09-17 2023-03-24 한국과학기술연구원 눈개승마 추출물을 유효성분으로 포함하는 건선 개선용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2002795B (en) * 1977-07-15 1982-03-17 Mallinckrodt Inc Nail enamel compositions their preparation and use
GB2085297B (en) * 1980-10-08 1984-06-13 Bernstein Joel Edward Composition for treating psoriasis of the fingernails
DE3045914A1 (de) * 1980-12-05 1982-07-22 Bayer Ag, 5090 Leverkusen Antimykotische mittel mit hoher wirkstoff-freisetzung in form von elastischen fluessig-pflastern
ATE84208T1 (de) * 1985-11-04 1993-01-15 Owen Galderma Lab Inc Filmbildende arzneimitteltraeger zur verabreichung von arzneimitteln an naegeln; verfahren zur verwendung.
HU219480B (hu) * 1991-05-23 2001-04-28 Novartis Ag. Eljárás gombás körömmegbetegségek ellen helyileg alkalmazható, allil-amin-származékot tartalmazó gyógyászati készítmények előállítására
EP0711181A1 (fr) * 1993-07-28 1996-05-15 Pfizer Inc. Traitement du psoriasis
DK128494A (da) * 1994-11-08 1996-05-09 Edel K Seidenschnur Behandling af keratinøse og psoriatiske sygdomstilstande med neglelak indeholdende vitamin D metabolit, eller derivat, og/eller vitamin A derivat

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9734644A1 *

Also Published As

Publication number Publication date
KR20000064607A (ko) 2000-11-06
WO1997034644A1 (fr) 1997-09-25
BR9708081A (pt) 1999-07-27
ZA972180B (en) 1997-09-16
CA2248977A1 (fr) 1997-09-25
AU1876797A (en) 1997-10-10
JP2000512265A (ja) 2000-09-19

Similar Documents

Publication Publication Date Title
EP0054279B1 (fr) Composition à libération retardée de nitroglycérine et sa méthode de préparation
EP0913154B1 (fr) Vernis à ongles antipsoriatique
DE69735598T2 (de) Progesterone zur behandlung oder minderung von ischemie in menopause befindlichen frauen, die östrogen bekommen
EP0298271B1 (fr) Email à ongles à activité antimycotique et procédé pour le préparer
EP0305493B1 (fr) Composition cosmetique de base ayant des proprietes therapeutiques
AT400518B (de) Nagellack zur behandlung von onychomykosis enthaltend terbinafine
DE4241874A1 (de) Medizinisches Pflaster für die perkutane Verabreichung
DE2933250A1 (de) Abdeckmaterial
EP0888138A1 (fr) Formulations topiques pour traiter le psoriasis de l'ongle
DE3690626C2 (de) Arzneimittel, enthaltend neben einer wirksamen Arzneistoffmenge ein Lacton oder cyclisches Keton
CH643456A5 (de) Pharmazeutische zubereitung.
DE60214207T2 (de) Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
EP0100458A2 (fr) Produit pour le traitement des plaies
EP0277462B1 (fr) Procèdè de fabrication de solutions nasales contenant de la calcitonine synthètique humaine.
DE69723725T2 (de) Verfahren zur herstellung von konzentrierten lösungen von fibronectin ohne puffer
DE2924042B1 (de) Filmibildende,verspruehbare Polymerisatloesung zur Herstellung eines Wundverbandes
DE3500755C2 (fr)
CA2251702A1 (fr) Composition biologiquement active
US5800831A (en) Psoriasis treatment with polymer film
DE3330628A1 (de) Hautschutz- und -pflegelotion
DE1266448B (de) Praeparat zum Entfernen lebloser verhornter Hautschichten
DE2852809C3 (de) Grundlage für Salben und Cremes
JPH0468286B2 (fr)
KR100220403B1 (ko) 각질 투과 증가제를 기제성분으로 함유하는 항진균성 손.발톱 와니스
AT412527B (de) Niedermolekulares nichtpolymeres gel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981016

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 981016;LV PAYMENT 981016;SI PAYMENT 981016

17Q First examination report despatched

Effective date: 20000516

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000927